Cargando…

Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery

PURPOSE: The role of axillary conservation after neoadjuvant chemotherapy (NACT) is debatable. We routinely carry out complete axillary lymph node dissection (ALND). This study was conducted to understand the pathologic axillary complete response (pAxCR) after NACT. MATERIALS AND METHODS: We evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Noronha, Jarin, Joshi, Shalaka, Hawaldar, Rohini, Nair, Nita, Vanmali, Vaibhav, Parmar, Vani, Shet, Tanuja, Badwe, Rajendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392778/
https://www.ncbi.nlm.nih.gov/pubmed/32735491
http://dx.doi.org/10.1200/GO.20.00195
_version_ 1783564916206075904
author Noronha, Jarin
Joshi, Shalaka
Hawaldar, Rohini
Nair, Nita
Vanmali, Vaibhav
Parmar, Vani
Shet, Tanuja
Badwe, Rajendra
author_facet Noronha, Jarin
Joshi, Shalaka
Hawaldar, Rohini
Nair, Nita
Vanmali, Vaibhav
Parmar, Vani
Shet, Tanuja
Badwe, Rajendra
author_sort Noronha, Jarin
collection PubMed
description PURPOSE: The role of axillary conservation after neoadjuvant chemotherapy (NACT) is debatable. We routinely carry out complete axillary lymph node dissection (ALND). This study was conducted to understand the pathologic axillary complete response (pAxCR) after NACT. MATERIALS AND METHODS: We evaluated a prospective database of patients with breast cancer who underwent surgery after NACT in the year 2017 at our institution. NACT was administered to downstage locally advanced breast cancer or facilitate breast-conservation surgery. RESULTS: Of 793 patients who underwent surgery after NACT, 97(12.2%) had cN0 disease, 407 (51.3%) had cN1, 262 (32%) had cN2, and 27 (3.4%) had cN3 at presentation. Eighty-eight patients (11.1%) had cT1-2 primary tumor stage, and 623 patients (78.6%) had cT3-4 primary tumor stage; primary tumor stage details were unavailable for 82 patients (10.3%). The median age was 46 years (range, 21-74 years). On histopathology, the overall pAxCR rate was 52.8%. In the cN1 and cN2 settings, 58.7% and 36.6% of patients achieved ypN0 status, respectively. The overall pathologic complete response rate was 22.64% (161 of 711 patients). On univariable analysis, cN stage, histologic grade, hormone receptor status, NACT duration, and lymphovascular invasion were significantly associated with pAxCR (P <.001). On logistic regression, prechemotherapy cN status (odds ratio [OR], 3.08; 95% CI, 2.18 to 4.37; P <.001), estrogen and progesterone receptor status (OR, 0.34; 95% CI, 0.3 to 0.4; P <.001), and administration of both chemotherapy regimens preoperatively (OR, 0.66; 95% CI, 0.45 to 0.97; P <.05) predicted pAxCR. CONCLUSION: At least half of patients with cN1 and a third of patients with cN2 breast cancer who develop pAxCR may be suitable candidates for axillary conservation. A careful postchemotherapy assessment followed by a conservative axillary procedure may be an alternative to ALND, but this needs to be studied prospectively.
format Online
Article
Text
id pubmed-7392778
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-73927782020-08-03 Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery Noronha, Jarin Joshi, Shalaka Hawaldar, Rohini Nair, Nita Vanmali, Vaibhav Parmar, Vani Shet, Tanuja Badwe, Rajendra JCO Glob Oncol Original Reports PURPOSE: The role of axillary conservation after neoadjuvant chemotherapy (NACT) is debatable. We routinely carry out complete axillary lymph node dissection (ALND). This study was conducted to understand the pathologic axillary complete response (pAxCR) after NACT. MATERIALS AND METHODS: We evaluated a prospective database of patients with breast cancer who underwent surgery after NACT in the year 2017 at our institution. NACT was administered to downstage locally advanced breast cancer or facilitate breast-conservation surgery. RESULTS: Of 793 patients who underwent surgery after NACT, 97(12.2%) had cN0 disease, 407 (51.3%) had cN1, 262 (32%) had cN2, and 27 (3.4%) had cN3 at presentation. Eighty-eight patients (11.1%) had cT1-2 primary tumor stage, and 623 patients (78.6%) had cT3-4 primary tumor stage; primary tumor stage details were unavailable for 82 patients (10.3%). The median age was 46 years (range, 21-74 years). On histopathology, the overall pAxCR rate was 52.8%. In the cN1 and cN2 settings, 58.7% and 36.6% of patients achieved ypN0 status, respectively. The overall pathologic complete response rate was 22.64% (161 of 711 patients). On univariable analysis, cN stage, histologic grade, hormone receptor status, NACT duration, and lymphovascular invasion were significantly associated with pAxCR (P <.001). On logistic regression, prechemotherapy cN status (odds ratio [OR], 3.08; 95% CI, 2.18 to 4.37; P <.001), estrogen and progesterone receptor status (OR, 0.34; 95% CI, 0.3 to 0.4; P <.001), and administration of both chemotherapy regimens preoperatively (OR, 0.66; 95% CI, 0.45 to 0.97; P <.05) predicted pAxCR. CONCLUSION: At least half of patients with cN1 and a third of patients with cN2 breast cancer who develop pAxCR may be suitable candidates for axillary conservation. A careful postchemotherapy assessment followed by a conservative axillary procedure may be an alternative to ALND, but this needs to be studied prospectively. American Society of Clinical Oncology 2020-07-31 /pmc/articles/PMC7392778/ /pubmed/32735491 http://dx.doi.org/10.1200/GO.20.00195 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Reports
Noronha, Jarin
Joshi, Shalaka
Hawaldar, Rohini
Nair, Nita
Vanmali, Vaibhav
Parmar, Vani
Shet, Tanuja
Badwe, Rajendra
Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery
title Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery
title_full Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery
title_fullStr Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery
title_full_unstemmed Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery
title_short Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery
title_sort sterilization rate of the axilla after neoadjuvant chemotherapy: the scope for conservative surgery
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392778/
https://www.ncbi.nlm.nih.gov/pubmed/32735491
http://dx.doi.org/10.1200/GO.20.00195
work_keys_str_mv AT noronhajarin sterilizationrateoftheaxillaafterneoadjuvantchemotherapythescopeforconservativesurgery
AT joshishalaka sterilizationrateoftheaxillaafterneoadjuvantchemotherapythescopeforconservativesurgery
AT hawaldarrohini sterilizationrateoftheaxillaafterneoadjuvantchemotherapythescopeforconservativesurgery
AT nairnita sterilizationrateoftheaxillaafterneoadjuvantchemotherapythescopeforconservativesurgery
AT vanmalivaibhav sterilizationrateoftheaxillaafterneoadjuvantchemotherapythescopeforconservativesurgery
AT parmarvani sterilizationrateoftheaxillaafterneoadjuvantchemotherapythescopeforconservativesurgery
AT shettanuja sterilizationrateoftheaxillaafterneoadjuvantchemotherapythescopeforconservativesurgery
AT badwerajendra sterilizationrateoftheaxillaafterneoadjuvantchemotherapythescopeforconservativesurgery